Our top pick for
Hill-Rom Holdings Inc is a medical instruments & supplies business based in the US. Hill-Rom shares (HRC) are listed on the NYSE and all prices are listed in US Dollars. Hill-Rom employs 10,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$154.72|
|52-week range||$85.80 - $154.92|
|50-day moving average||$151.04|
|200-day moving average||$126.90|
|Wall St. target price||$155.75|
|Dividend yield||$0.92 (0.6%)|
|Earnings per share (TTM)||$3.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||2.46%|
|1 month (2021-09-24)||3.15%|
|3 months (2021-07-23)||27.63%|
|6 months (2021-04-23)||33.47%|
|1 year (2020-10-23)||67.48%|
|2 years (2019-10-24)||56.77%|
|3 years (2018-10-24)||85.12%|
|5 years (2016-10-24)||159.21%|
Valuing Hill-Rom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hill-Rom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hill-Rom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, Hill-Rom shares trade at around 43x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Hill-Rom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.71. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hill-Rom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Hill-Rom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $574.6 million.
The EBITDA is a measure of a Hill-Rom's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.9 billion|
|Operating margin TTM||13.68%|
|Gross profit TTM||$1.5 billion|
|Return on assets TTM||5.38%|
|Return on equity TTM||13.68%|
|Market capitalisation||$10.2 billion|
TTM: trailing 12 months
There are currently 4.2 million Hill-Rom shares held short by investors – that's known as Hill-Rom's "short interest". This figure is 444.7% up from 765,649 last month.
There are a few different ways that this level of interest in shorting Hill-Rom shares can be evaluated.
Hill-Rom's "short interest ratio" (SIR) is the quantity of Hill-Rom shares currently shorted divided by the average quantity of Hill-Rom shares traded daily (recently around 2.0 million). Hill-Rom's SIR currently stands at 2.06. In other words for every 100,000 Hill-Rom shares traded daily on the market, roughly 2060 shares are currently held short.
However Hill-Rom's short interest can also be evaluated against the total number of Hill-Rom shares, or, against the total number of tradable Hill-Rom shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hill-Rom's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Hill-Rom shares in existence, roughly 60 shares are currently held short) or 0.0809% of the tradable shares (for every 100,000 tradable Hill-Rom shares, roughly 81 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hill-Rom.
Find out more about how you can short Hill-Rom stock.
Dividend payout ratio: 16.18% of net profits
Recently Hill-Rom has paid out, on average, around 16.18% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.62% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Hill-Rom shareholders could enjoy a 0.62% return on their shares, in the form of dividend payments. In Hill-Rom's case, that would currently equate to about $0.92 per share.
While Hill-Rom's payout ratio might seem low, this can signify that Hill-Rom is investing more in its future growth.
Hill-Rom's most recent dividend payout was on 29 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 15 September 2021 (the "ex-dividend date").
Hill-Rom's shares were split on a 10000:5366 basis on 31 March 2008. So if you had owned 5366 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Hill-Rom shares – just the quantity. However, indirectly, the new 46.3% lower share price could have impacted the market appetite for Hill-Rom shares which in turn could have impacted Hill-Rom's share price.
Over the last 12 months, Hill-Rom's shares have ranged in value from as little as $85.797 up to $154.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Hill-Rom's is 0.5788. This would suggest that Hill-Rom's shares are less volatile than average (for this exchange).
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising non-invasive devices that provide respiratory support and assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include tables, lights, and pendants; and positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells and rents products to acute and extended care facilities through direct sales force and distributors; sells and rents products directly to patients in the home; and sells products to primary care facilities through distributors.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.